ECSP19084058A - Métodos y composiciones para el tratamiento de apnea del sueño - Google Patents

Métodos y composiciones para el tratamiento de apnea del sueño

Info

Publication number
ECSP19084058A
ECSP19084058A ECSENADI201984058A ECDI201984058A ECSP19084058A EC SP19084058 A ECSP19084058 A EC SP19084058A EC SENADI201984058 A ECSENADI201984058 A EC SENADI201984058A EC DI201984058 A ECDI201984058 A EC DI201984058A EC SP19084058 A ECSP19084058 A EC SP19084058A
Authority
EC
Ecuador
Prior art keywords
compositions
treatment
methods
sleep apnea
nri
Prior art date
Application number
ECSENADI201984058A
Other languages
English (en)
Inventor
Taranto-Montemurro Luigi
Wellman D Andrew
Original Assignee
The Brigham And Women´S Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63918622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19084058(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Brigham And Women´S Hospital Inc filed Critical The Brigham And Women´S Hospital Inc
Publication of ECSP19084058A publication Critical patent/ECSP19084058A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Métodos y composiciones para el tratamiento de afecciones asociadas al colapso muscular de la vía aérea faríngea mientras el sujeto está en un estado no completamente consciente, por ejemplo, apnea del sueño y ronquidos, que comprende la administración de un inhibidor de la recaptación de noradrenalina (NRI) y un antagonista de los receptores muscarínicos.
ECSENADI201984058A 2017-04-28 2019-11-25 Métodos y composiciones para el tratamiento de apnea del sueño ECSP19084058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491504P 2017-04-28 2017-04-28
US201762558814P 2017-09-14 2017-09-14

Publications (1)

Publication Number Publication Date
ECSP19084058A true ECSP19084058A (es) 2020-01-31

Family

ID=63918622

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201984058A ECSP19084058A (es) 2017-04-28 2019-11-25 Métodos y composiciones para el tratamiento de apnea del sueño

Country Status (22)

Country Link
US (3) US11123313B2 (es)
EP (1) EP3615016A4 (es)
JP (2) JP7373997B2 (es)
KR (2) KR20190140019A (es)
CN (1) CN110799181A (es)
AU (2) AU2018260666B2 (es)
BR (1) BR112019022483A2 (es)
CA (1) CA3061468A1 (es)
CO (1) CO2019013180A2 (es)
CR (1) CR20190546A (es)
DO (1) DOP2019000274A (es)
EC (1) ECSP19084058A (es)
GE (2) GEP20247617B (es)
MA (1) MA49069A (es)
MX (2) MX2019012729A (es)
MY (1) MY200172A (es)
NI (1) NI201900110A (es)
PH (1) PH12019502427A1 (es)
SG (2) SG10202111623TA (es)
UA (1) UA127759C2 (es)
WO (1) WO2018200775A1 (es)
ZA (1) ZA201907158B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202111623TA (en) * 2017-04-28 2021-12-30 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
MA52861A (fr) 2018-01-30 2021-05-05 Apnimed Inc Delaware Méthodes et compositions pour le traitement de l'apnée du sommeil
CN108309261B (zh) * 2018-02-11 2020-05-22 西安交通大学 一种猝死预警方法及装置和系统
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
CN112930179A (zh) * 2018-10-31 2021-06-08 爱普宁公司(特拉华) 治疗睡眠呼吸暂停的方法和组合物
JP2022519721A (ja) * 2019-02-08 2022-03-24 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 睡眠時無呼吸を治療するための方法および組成物
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
RU2757470C1 (ru) * 2020-11-19 2021-10-18 Ренат Рашитович Ахмеров Способ лечения храпа с помощью введения тромбоцитарной аутологичной плазмы
WO2022155162A1 (en) * 2021-01-14 2022-07-21 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
CA3210092A1 (en) * 2021-03-04 2022-09-09 Lawrence G. Miller Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
AU2022259671A1 (en) * 2021-04-16 2023-11-09 Apnimed, Inc. (Delaware) Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
WO2022266440A1 (en) * 2021-06-17 2022-12-22 Apnimed, Inc. (Delaware) Norepinephrine reuptake inhibitors for treating sleep apnea
KR20240053061A (ko) * 2021-08-31 2024-04-23 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
TW202342011A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與蕈毒鹼受體拮抗劑之組合
TW202342052A (zh) * 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之ｔａｓｋ１／３通道阻斷劑與正腎上腺素再吸收抑制劑之組合
TW202342033A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與正腎上腺素再吸收抑制劑之組合
WO2023219991A1 (en) * 2022-05-13 2023-11-16 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
JP2003523382A (ja) * 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
CA2590802A1 (en) 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
EP2672972B1 (en) * 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Methods for treating obstructive sleep apnea
SG10202111623TA (en) * 2017-04-28 2021-12-30 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
MA52861A (fr) * 2018-01-30 2021-05-05 Apnimed Inc Delaware Méthodes et compositions pour le traitement de l'apnée du sommeil

Also Published As

Publication number Publication date
US11123313B2 (en) 2021-09-21
GEP20247617B (en) 2024-04-25
KR20240042261A (ko) 2024-04-01
WO2018200775A1 (en) 2018-11-01
ZA201907158B (en) 2021-09-29
NZ758564A (en) 2023-12-22
MX2019012729A (es) 2019-12-19
JP7373997B2 (ja) 2023-11-06
NI201900110A (es) 2020-03-18
GEP20227387B (en) 2022-06-10
US20200054583A1 (en) 2020-02-20
BR112019022483A2 (pt) 2020-05-12
JP2020517719A (ja) 2020-06-18
DOP2019000274A (es) 2019-12-30
AU2018260666A1 (en) 2019-11-14
SG11201909973UA (en) 2019-11-28
US20240189261A1 (en) 2024-06-13
MA49069A (fr) 2020-03-04
CA3061468A1 (en) 2018-11-01
JP2023139000A (ja) 2023-10-03
AU2022241471A1 (en) 2022-10-27
CN110799181A (zh) 2020-02-14
EP3615016A1 (en) 2020-03-04
CR20190546A (es) 2020-04-08
US20210401777A1 (en) 2021-12-30
EP3615016A4 (en) 2021-02-24
UA127759C2 (uk) 2023-12-27
SG10202111623TA (en) 2021-12-30
KR20190140019A (ko) 2019-12-18
PH12019502427A1 (en) 2020-10-05
AU2018260666B2 (en) 2022-07-21
CO2019013180A2 (es) 2020-02-07
MY200172A (en) 2023-12-12
MX2022010349A (es) 2022-09-19

Similar Documents

Publication Publication Date Title
CO2019013180A2 (es) Métodos y composiciones para el tratamiento de apnea del sueño
MX2021009407A (es) Métodos y composiciones para el tratamiento de la apnea del sueño.
DOP2018000142A (es) Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
DOP2019000171A (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
MX2020008086A (es) Metodos y composiciones para tratar la apnea del sue?o.
DOP2019000172A (es) Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
BR112017025000A2 (pt) tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
PA8824601A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia
CL2023002824A1 (es) Métodos y composiciones para tratar la apnea del sueño
CL2007002324A1 (es) Compuestos derivados de 1h-quinolin-4-ona; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar o prevenir enfermedades asociadas con la modulacion del receptor gaba a, ansiedad, epilepsia, trastornos del sueno, insomnio, induccion de sedacion-hipnosis, anestesia y relajacion muscular.
ECSP15033649A (es) Un medicamento combinado que comprende fenilefrina y paracetamol
CL2015003679A1 (es) Agentes terapéuticos para el uso en la profilaxis y/o el tratamiento de trastornos del movimiento hiperquineticoico
EA201992569A1 (ru) Способы и композиции для лечения апноэ во сне
NZ758564B2 (en) Methods and compositions for treating sleep apnea
CO7160013A1 (es) Cinturón para detectar, corregir, prevenir y monitorear la apnea del sueño
BR112014029577A2 (pt) uso de agonistas ou antagonistas inversos do receptor de grelina para tratamento de transtornos do sono
CL2021001315A1 (es) Antagonistas de los adrenoreceptores a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño
EA201991538A1 (ru) Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3, и их применение для лечения нарушений дыхания
MY197162A (en) Use of a composition for suppressing metabolic syndrome and osteoporosis
Ghiggia et al. Alexithymia in Fibromyalgia Syndrome: is it a discriminant factor?
TH174259A (th) สารปรับเปลี่ยนตัวรับ nmda และโพรดรัก, เกลือ, และการใช้สิ่งเหล่านี้